3‐carboxy‐4‐methyl‐5‐propyl‐2‐furanpropanoic acid (CMPF) prevents high fat diet‐induced insulin resistance via maintenance of hepatic lipid homeostasis

Mohan, Haneesha; Brandt, Sydney L.; Kim, Ja Hyun; Wong, Frances; Lai, Mi; Prentice, Kacey J.; Rijjal, Dana Al; Magomedova, Lilia; Batchuluun, Battsetseg; Burdett, Elena; Bhattacharjee, Ananya; Cummins, Carolyn L.; Belsham, Denise D.; Cox, Brian; Liu, Ying; Wheeler, Michael B.

doi:10.1111/dom.13483

Cited by 13 publications

(15 citation statements)

References 42 publications

(102 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The present data show a divergent association, as we know that the serum HDL-c levels are often negatively related to TG levels, and CMPF was independently negatively associated with HDL-c and triglycerides. However, the present results were consistent with another study showing that CMPF treatment reduced circulating TG and HDL-c levels in mice 23 . The negative relationships of CMPF levels with both HDL-c and TG levels were not in conflict, since the different transcription factors and rate-limiting enzyme were affected by CMPF in TG or cholesterol biosynthesis 23 .…”

Section: Discussionsupporting

confidence: 94%

“…However, the present results were consistent with another study showing that CMPF treatment reduced circulating TG and HDL-c levels in mice 23 . The negative relationships of CMPF levels with both HDL-c and TG levels were not in conflict, since the different transcription factors and rate-limiting enzyme were affected by CMPF in TG or cholesterol biosynthesis 23 . A study showed that a high baseline log (TG)/HDL-C ratio predicts fast progression of islet bcell dysfunction 24 , so the negative association between CMPF and HDL-c might be an explanation for elevated CMPF levels in type 2 diabetes mellitus patients.…”

Section: Discussionsupporting

confidence: 94%

See 1 more Smart Citation

Serum 3‐carboxy‐4‐methyl‐5‐propyl‐2‐furanpropanoic acid is associated with lipid profiles and might protect against non‐alcoholic fatty liver disease in Chinese individuals

Dai

Zhang

et al. 2018

J of Diabetes Invest

View full text Add to dashboard Cite

Aims/Introduction High plasma 3‐carboxy‐4‐methyl‐5‐propyl‐2‐furanpropanoic acid ( CMPF ) levels are significantly associated with type 2 diabetes mellitus, which is usually accompanied by metabolic syndrome and non‐alcoholic fatty liver disease ( NAFLD ) with increased triglyceride levels. Thus, we hypothesized that elevated CMPF levels might be related to lipid metabolism and NAFLD risk. Materials and Methods Serum CMPF levels were determined using an enzyme‐linked immunosorbent assay in a total of 466 individuals, including 116 controls with no NAFLD or type 2 diabetes mellitus, 53 individuals with NAFLD but no type 2 diabetes mellitus, 151 individuals with type 2 diabetes mellitus but no NAFLD, and 146 individuals with both NAFLD and type 2 diabetes mellitus. The associations with age, blood pressure, lipid profiles, body mass index and liver injury marker levels were examined, and a meta‐analysis of non‐diabetic and diabetic groups was carried out to detect the combined effects. Results The CMPF concentration in NAFLD patients was significantly lower than individuals without NAFLD in both the non‐diabetic group ( P < 0.05) and diabetic group ( P < 0.01), and correlated negatively with several parameters of liver function and the adiposity index. Meta‐analysis showed that serum CMPF levels was associated with decreased risk of NAFLD after combining the results (odds ratio 0.677, 95% confidence interval 0.552–0.831, P < 0.001). Additionally, the CMPF concentration was independently negatively associated with triglycerides and high‐density lipoprotein cholesterol in the meta‐analysis. Multiple stepwise regression analysis showed that body mass index , high‐density lipoprotein cholesterol, triglyceride level, age, sex and fasting plasma glucose were independently associated with CMPF (all P < 0.05). Conclusions The results suggest that serum CMPF levels are negatively related to lipid metabolism and could be used to predict NAFLD development.

show abstract

Section: Discussionsupporting

confidence: 94%

Section: Discussionsupporting

confidence: 94%

Serum 3‐carboxy‐4‐methyl‐5‐propyl‐2‐furanpropanoic acid is associated with lipid profiles and might protect against non‐alcoholic fatty liver disease in Chinese individuals

Dai

Zhang

et al. 2018

J of Diabetes Invest

View full text Add to dashboard Cite

show abstract

“…An OGTT and an intraperitoneal insulin tolerance test (IPITT) were performed as described previously ( Liu et al., 2016 ; Mohan et al., 2019 ; Prentice et al., 2014 ). Following a 15 hr overnight fast, an OGTT was performed in which mice were orally gavaged with glucose (Cat# 50-99-7, Sigma Aldrich) at 2g/kg and glucose levels were measured for 2 hr at time points 0, 10, 20, 30, 60, 90 and 120 min using a glucometer (Bayer Contour NEXT ONE Glucose meter, Ascensia Diabetes Care, Canada).…”

Section: Methodsmentioning

confidence: 99%

Vascepa protects against high-fat diet-induced glucose intolerance, insulin resistance, and impaired β-cell function

et al. 2021

Self Cite

View full text Add to dashboard Cite

Summary Omega-3 fatty acid prescription drugs, Vascepa (≥96% eicosapentaenoic acid [EPA] ethyl ester) and Lovaza (46.5% EPA and 37.5% docosahexaenoic acid ethyl ester) are known therapeutic regimens to treat hypertriglyceridemia. However, their impact on glucose homeostasis, progression to type 2 diabetes, and pancreatic beta cell function are not well understood. In the present study, mice were treated with Vascepa or Lovaza for one week prior to six weeks of high-fat diet feeding. Vascepa but not Lovaza led to reduced insulin resistance, reduced fasting insulin and glucose, and improved glucose intolerance. Vascepa improved beta cell function, reduced liver triglycerides with enhanced expression of hepatic fatty acid oxidation genes, and altered microbiota composition. Vascepa has protective effects on diet-induced insulin resistance and glucose intolerance in mice.

show abstract

“…Moreover, in vitro FuFAs modulate lipid metabolism in adipose tissues (Lengler et al, 2012;Lauvai et al, 2019). The 3-carboxy-4methyl-5-propyl-2-furanpropanoic acid (CMPF), a degradation product of FuFAs, also derived from the metabolism of n-3 PUFAs, could prevent or even reverse hepatic steatosis (Prentice et al, 2018;Dai et al, 2019;Mohan et al, 2019). Alvarado et al recently published a comprehensive review on FuFAs (Alvarado et al, 2021).…”

Section: Health Effectsmentioning

confidence: 99%

Potential favourable health effects of some dietary uncommon fatty acids

Coudray

Durand

Balas

et al. 2021

OCL

View full text Add to dashboard Cite

In addition to the major fatty acids widely studied, our diet contains many bioactive fatty acids less frequently investigated such as n-3 docosapentaenoic acid (n-3 DPA), natural trans fatty acids, conjugated fatty acids (CLAs), furan fatty acids (FuFAs), branched chain fatty acids (BCFAs) and fatty acid esters of hydroxyl fatty acids (FAHFAs). Many of them may have beneficial health effects, particularly in the prevention of cardiovascular diseases, inflammation and metabolic disorders such as diabetes. This review aims to give a brief overview of the current knowledge on these lipids. Thus, information about biosynthesis, food and tissue content, daily intake, biological and potential health effects of these fatty acids is provided.

show abstract

3‐carboxy‐4‐methyl‐5‐propyl‐2‐furanpropanoic acid (CMPF) prevents high fat diet‐induced insulin resistance via maintenance of hepatic lipid homeostasis

Abstract: CMPF is a potential driver of hepatic lipid metabolism, preventing diet-induced hepatic lipid deposition and insulin resistance in the long term.

Cited by 13 publications

References 42 publications

Serum 3‐carboxy‐4‐methyl‐5‐propyl‐2‐furanpropanoic acid is associated with lipid profiles and might protect against non‐alcoholic fatty liver disease in Chinese individuals

Serum 3‐carboxy‐4‐methyl‐5‐propyl‐2‐furanpropanoic acid is associated with lipid profiles and might protect against non‐alcoholic fatty liver disease in Chinese individuals

Vascepa protects against high-fat diet-induced glucose intolerance, insulin resistance, and impaired β-cell function

Potential favourable health effects of some dietary uncommon fatty acids

Contact Info

Product

Resources

About